Trial Profile
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary)
- Indications Asthma; Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 11 Aug 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.